1-去氧-D-山梨醇 | 18545-96-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-去氧-D-山梨醇
• 英文名称: 1-deoxy-D-glucitol
• 英文别名: 1-Desoxy-D-glucit；(2R,3R,4R,5S)-hexane-1,2,3,4,5-pentol
• CAS: 18545-96-5
• 化学式: C₆H₁₄O₅
• 分子量: 166.174
• InChiKey: SKCKOFZKJLZSFA-SLPGGIOYSA-N

物化性质

• 熔点：
  128-129 °C
• 沸点：
  468.0±40.0 °C(Predicted)
• 密度：
  1.424±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  101
• 氢给体数：
  5
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-去氧-D-山梨醇 在 吡啶 、 盐酸 作用下， 生成 O⁶-acetyl-O²,O⁴;O³,O⁵-dimethanediyl-1-deoxy-D-glucitol
  参考文献：
  名称：

  Wolfrom; Lew; Goepp, Journal of the American Chemical Society, 1946, vol. 68, p. 1447

  摘要：

  DOI：
• 作为产物：
  描述：

  D-葡萄糖-二乙基缩硫醛 在 Raney nickel 作用下， 以 乙醇 为溶剂， 反应 5.0h， 生成 1-去氧-D-山梨醇
  参考文献：
  名称：

  Identification of catabolic pathway for 1-deoxy-D-sorbitol in Bacillus licheniformis

  摘要：

  1-Deoxy-D-sorbitol, the 1-deoxy analogue of D-sorbitol, has been detected in human urine as well as in natural herbs and spices. Although there are sporadic reports about 1-deoxy-D-sorbitol dehydrogenase, the complete catabolic pathway of 1-deoxy-D-sorbitol remains unsolved. Informed by the promiscuous activities of fructose-6-phosphate aldolase (FSA) which is involved in the sorbitol (glucitol) utilization (gut) operon and guided by the large scale bioinformatics analysis, we predicted and then experimentally verified the gut operon encoded by Bacillus licheniformis ATCC14580 is responsible for the catabolism of both D-sorbitol and 1-deoxy-D-sorbitol by in vitro activity assays of pathway enzymes, in vivo growth phenotypes, and transcriptomic studies. Moreover, the phylogenetic distribution analysis suggests that the D-sorbitol and 1-deoxy-D-sorbitol catabolic gene cluster is mostly conserved in members of Firmicutes phylum.

  DOI：

  10.1016/j.bbrc.2021.11.072

文献信息

• [EN] METABOLICALLY ROBUST ANALOGS OF CYP-EICOSANOIDS FOR THE TREATMENT OF CARDIAC DISEASE<br/>[FR] ANALOGUES ROBUSTES SUR LE PLAN MÉTABOLIQUE DES CYP-EICOSANOÏDES POUR LE TRAITEMENT DES MALADIES CARDIAQUES
  申请人：OMEICOS THERAPEUTICS GMBH

  公开号：WO2017013265A1

  公开（公告）日：2017-01-26

  The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs).The present invention further relates to compositions containing one or more of these compounds and to the use of these compounds or compositions for the treatment or prevention of cardiovascular diseases.

  本发明涉及符合一般式（I）的化合物，这些化合物是从ω-3多不饱和脂肪酸（n-3 PUFAs）衍生的生物活性脂质介质的代谢稳健类似物。本发明还涉及含有这些化合物中的一个或多个的组合物，以及利用这些化合物或组合物治疗或预防心血管疾病。
• DEOXYKETOHEXOSE ISOMERASE AND METHOD FOR PRODUCING DEOXYHEXOSE AND DERIVATIVE THEREOF USING SAME
  申请人：Izumori Ken

  公开号：US20100105885A1

  公开（公告）日：2010-04-29

  Providing 1- or 6-deoxy products corresponding to all of aldohexoses, ketohexoses and sugar alcohols, as based on Deoxy-Izumoring, as well as a method for systematically producing those products. A method for producing deoxyketohexose and a derivative thereof using a deoxyketohexose isomerase derived from Pseudomonas cichorii ST-24 (FERM BP-2736), comprising epimerizing 1-deoxy D-ketohexose or 6-deoxy D-ketohexose or 1-deoxy L-ketohexose or 6-deoxy L-ketohexose at position 3 to produce the individually corresponding 1-deoxy D-ketohexose or 6-deoxy D-ketohexose or 1-deoxy L-ketohexose or 6-deoxy L-ketohexose as an intended product.

  提供对应于所有己醛糖、己酮糖和糖醇的1-或6-去氧产物，基于去氧-Izumoring，以及一种系统生产这些产物的方法。一种使用来自Pseudomonas cichoriiST-24（FERM BP-2736）的去氧己酮糖异构酶生产去氧己酮糖及其衍生物的方法，包括将1-去氧D-己酮糖或6-去氧D-己酮糖或1-去氧L-己酮糖或6-去氧L-己酮糖在3号位置上对映异构化为各自对应的1-去氧D-己酮糖或6-去氧D-己酮糖或1-去氧L-己酮糖或6-去氧L-己酮糖作为预期产物。
• [EN] ANALOGS OF CYP-EICOSANOIDS FOR USE IN TREATING OR PREVENTING A DISORDER ASSOCIATED WITH NEOVASCULARIZATION AND/OR INFLAMMATION<br/>[FR] ANALOGUES DE CYP-ÉICOSANOÏDES POUR UTILISATION DANS LE TRAITEMENT PROPHYLACTIQUE OU THÉRAPEUTIQUE D'UN TROUBLE ASSOCIÉ À UNE NÉOVASCULARISATION ET/OU UNE INFLAMMATION
  申请人：OMEICOS THERAPEUTICS GMBH

  公开号：WO2017168007A1

  公开（公告）日：2017-10-05

  The present invention relates to compounds according to general formula (I) which are metabolically robust analogues of bioactive lipid mediators derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs) for use in treating or reducing the risk of developing or preventing: (i) neovascularization and/or (ii) inflammatory disorder, in particular, ophthalmic disorders associated with neovascularization and/or inflammation.

  本发明涉及符合一般式(I)的化合物，这些化合物是从ω-3多不饱和脂肪酸(n-3 PUFAs)衍生的代谢稳健的生物活性脂质介质的类似物，用于治疗或减少发展或预防：(i) 新生血管生成和/或(ii) 炎症性疾病，特别是与新生血管生成和/或炎症相关的眼科疾病。
• Process for the Preparation of ß-C-Aryl Glucosides
  申请人：ScinoPharm Taiwan, LTD.

  公开号：US20140128595A1

  公开（公告）日：2014-05-08

  The present invention provides processes for stereoselectively preparing C-arylglucosides that can be useful as synthetic building block or drugs, including SGLT2 inhibitors.

  本发明提供了用于立体选择性制备C-芳基葡萄糖苷的方法，这些方法可以作为合成建筑模块或药物使用，包括SGLT2抑制剂。
• [EN] NOVEL CYP-EICOSANOID DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS CYP-ÉICOSANOÏDE
  申请人：MAX DELBRÜCK CT FÜR MOLEKULARE MEDIZIN

  公开号：WO2015110262A1

  公开（公告）日：2015-07-30

  The present invention relates to compounds according to general formula (I) which are analogues of epoxymetabolites produced by cytochrome P450 (CYP) enzymes from omega-3 (n-3) polyunsaturated fatty acids (PUFAs). The present invention further relates to compositions containing one or more of these compounds and to the use of these compounds or compositions for the treatment or prevention of conditions and diseases associated with inflammation, proliferation, hypertension, coagulation, immune function, pathologic angiogenesis, heart failure and cardiac arrhythmias.

  本发明涉及一般式（I）的化合物，这些化合物是由细胞色素P450（CYP）酶从ω-3（n-3）多不饱和脂肪酸（PUFAs）产生的环氧代谢产物的类似物。本发明还涉及含有这些化合物中的一个或多个的组合物，以及利用这些化合物或组合物治疗或预防与炎症、增殖、高血压、凝血、免疫功能、病理性血管生成、心力衰竭和心律失常相关的疾病和症状。